CytoMed Therapeutics Limited Statistics
Want to see GDTC full AI Analyst Report?
CytoMed Therapeutics Limited (GDTC) Stock Statistics & Valuation Metrics
Total Valuation
CytoMed Therapeutics Limited has a market cap or net worth of $9.89M. The enterprise value is $11.79M.
- Market Cap
- $9.89M
- Enterprise Value
- $11.79M
Share Statistics
CytoMed Therapeutics Limited has 11,832,835 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 11,832,835
- Owned by Insiders
- 14.66%
- Owned by Institutions
- 0.23%
Financial Efficiency
CytoMed Therapeutics Limited’s return on equity (ROE) is -0.61 and return on invested capital (ROIC) is -65.28%.
- Return on Equity (ROE)
- -0.61
- Return on Assets (ROA)
- -0.50
- Return on Invested Capital (ROIC)
- -65.28%
- Return on Capital Employed (ROCE)
- -0.66
- Revenue Per Employee
- 7,723.5
- Profits Per Employee
- -94.77K
- Employee Count
- 42
- Asset Turnover
- 0.04
- Inventory Turnover
- 0.06
Valuation Ratios
The current PE Ratio of CytoMed Therapeutics Limited is -2.44. CytoMed Therapeutics Limited’s PEG ratio is -0.30.
- PE Ratio
- -2.44
- PS Ratio
- 17.60
- PB Ratio
- 2.56
- Price to FCF
- -2.01
- Price to Operating Cash Flow
- -2.28
- PEG Ratio
- -0.30
Income Statement
In the last 12 months, CytoMed Therapeutics Limited had revenue of 324.39K and earned -3.98M in profits. Earnings per share was -0.34.
- Revenue
- 324.39K
- Gross Profit
- 256.39K
- Operating Income
- -4.79M
- Pretax Income
- -4.00M
- Net Income
- -3.98M
- EBITDA
- -3.57M
- Earnings Per Share (EPS)
- -0.34
Cash Flow
In the last 12 months, operating cash flow was -5.58M and capital expenditures -723,136, giving a free cash flow of -6.30M billion.
- Operating Cash Flow
- -5.58M
- Free Cash Flow
- -6.30M
- Free Cash Flow per Share
- -0.53
Dividends & Yields
CytoMed Therapeutics Limited pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -50.05%
- Earnings Yield
- -41.62%
Stock Price Statistics
- Beta
- 0.06
- 52-Week Price Change
- -57.61%
- 50-Day Moving Average
- 0.89
- 200-Day Moving Average
- 0.98
- Relative Strength Index (RSI)
- 41.91
- Average Volume (3m)
- 17.79K
Important Dates
CytoMed Therapeutics Limited upcoming earnings date is ―, TBA (Confirmed).
- Last Earnings Date
- May 04, 2026
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
CytoMed Therapeutics Limited as a current ratio of 5.17, with Debt / Equity ratio of 7.37%
- Current Ratio
- 5.17
- Quick Ratio
- 3.66
- Debt to Market Cap
- 0.02
- Net Debt to EBITDA
- 0.45
- Interest Coverage Ratio
- -229.08
Taxes
In the past 12 months, CytoMed Therapeutics Limited has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
CytoMed Therapeutics Limited EV to EBITDA ratio is -2.40, with an EV/FCF ratio of -1.84.
- EV to Sales
- 16.09
- EV to EBITDA
- -2.40
- EV to Free Cash Flow
- -1.84
- EV to Operating Cash Flow
- -2.08
Balance Sheet
CytoMed Therapeutics Limited has $1.46M in cash and marketable securities with $453.76K in debt, giving a net cash position of $1.00M billion.
- Cash & Marketable Securities
- $1.46M
- Total Debt
- $453.76K
- Net Cash
- $1.00M
- Net Cash Per Share
- $0.08
- Tangible Book Value Per Share
- $0.45
Margins
Gross margin is -577.72%, with operating margin of -794.57%, and net profit margin of -730.34%.
- Gross Margin
- -577.72%
- Operating Margin
- -794.57%
- Pretax Margin
- -738.15%
- Net Profit Margin
- -730.34%
- EBITDA Margin
- -671.27%
- EBIT Margin
- -766.83%
Analyst Forecast
The average price target for CytoMed Therapeutics Limited is $4.16, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $4.16
- Price Target Upside
- 398.20% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- 49.09%
- EPS Growth Forecast
- 3.91%
Scores
- Smart Score
- ―
- AI Score
- 43
